Abbott (ABT) has successfully completed the first-ever in-human procedures using its investigational AVEIR Conduction System, a leadless pacemaker designed for left bundle branch area pacing, as part of a feasibility study. This study, known as the Leadless CSP feasibility study, assesses the immediate safety and effectiveness of the AVEIR CSP leadless pacemaker system. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Abbott's AVEIR CSP system, underscoring its potential to advance left bundle branch area pacing techniques.
The material has been provided by InstaForex Company - www.instaforex.com
The material has been provided by InstaForex Company - www.instaforex.com